Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Return on Capital Employed (2021 - 2026)

Cytek Biosciences filings provide 5 years of Return on Capital Employed readings, the most recent being 10.09% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 529.0% to 10.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 10.09%, a 529.0% decrease, with the full-year FY2025 number at 10.03%, down 525.0% from a year prior.
  • Return on Capital Employed hit 10.09% in Q4 2025 for Cytek Biosciences, down from 7.59% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 5.03% in Q3 2021 to a low of 10.09% in Q4 2025.
  • Median Return on Capital Employed over the past 5 years was 5.18% (2024), compared with a mean of 3.5%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -583bps in 2023 and later skyrocketed 138bps in 2024.
  • Cytek Biosciences' Return on Capital Employed stood at 2.15% in 2021, then plummeted by -118bps to 0.39% in 2022, then plummeted by -1477bps to 6.18% in 2023, then increased by 22bps to 4.8% in 2024, then tumbled by -110bps to 10.09% in 2025.
  • The last three reported values for Return on Capital Employed were 10.09% (Q4 2025), 7.59% (Q3 2025), and 6.48% (Q2 2025) per Business Quant data.